Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review
Adverse events Respiratory infection (pneumonia) Nasal mucosa or skin trauma · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in adverse events Respiratory infection (pneumonia) Nasal mucosa or… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review
Duration of ICU stay · adults in the ICU, requiring respiratory support
1 finding from 1 review
Respiratory effects: PaO2/FiO2 ratio up to 24 hours after initiation of therapy · adults in the ICU, requiring respiratory support
1 finding from 1 review
Comfort · adults in the ICU, requiring respiratory support
2 findings from 1 review
Treatment failure (escalation of respiratory therapy to NIV, NIPPV or invasive ventilation) Measured up to 28 days · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in treatment failure (escalation of respiratory therapy to NIV, NIPPV… compared with NIPPV or NIV (low certainty).
1 finding from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with NIPPV or NIV (low certainty).
1 finding from 1 review
Length of delirium episode · end‐of‐life patients with advanced cancer and an episode of agitated delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality from all causes · adult AIDS patients with delirium
It is very uncertain whether benzodiazepines (lorazepam) changes mortality from all causes compared with antipsychotics (chlorpromazine) (very low certainty).
1 finding from 1 review
Length of delirium episode · adult AIDS patients with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of delirium · adult AIDS patients with delirium
1 finding from 1 review
Any adverse event ESRS, higher = worse · adult AIDS patients with delirium
1 finding from 1 review
Duration of hospital admission (days) · adult AIDS patients with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality from all causes · adult AIDS patients with delirium
It is very uncertain whether benzodiazepines (lorazepam) changes mortality from all causes compared with antipsychotics (haloperidol) (very low certainty).
1 finding from 1 review
Severity of delirium · end‐of‐life patients with advanced cancer and an episode of agitated delirium
1 finding from 1 review
Any adverse event · end‐of‐life patients with advanced cancer and an episode of agitated delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · end‐of‐life patients with advanced cancer and an episode of agitated delirium
1 finding from 1 review
Mortality from all causes · end‐of‐life patients with advanced cancer and an episode of agitated delirium
Benzodiazepines (lorazepam) showed no clear difference in mortality from all causes compared with placebo (low certainty).
1 finding from 1 review